Commercial Launch Plans Announced for PERSERIS(TM) (risperidone) Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults

Indivior PLC Announces Plan for Commercial Launch in February 2019 with 50 Sales Representatives CUPERTINO, Calif., Dec. 19, 2018 -- (Healthcare Sales & Marketing Network) -- DURECT Corporation (Nasdaq: DRRX) today announced that Indivior PLC (LON: IND... Biopharmaceuticals, Product Launch DURECT, PERSERIS, risperidone, Schizophrenia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news